Sono-Tek (NASDAQ:SOTK – Get Free Report) was upgraded by equities researchers at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Tuesday,Zacks.com reports.
Separately, Weiss Ratings reiterated a “sell (d+)” rating on shares of Sono-Tek in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $7.50.
View Our Latest Report on Sono-Tek
Sono-Tek Stock Performance
Sono-Tek (NASDAQ:SOTK – Get Free Report) last issued its quarterly earnings data on Tuesday, October 14th. The industrial products company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.01. Sono-Tek had a net margin of 7.33% and a return on equity of 8.48%. The business had revenue of $5.16 million for the quarter, compared to analysts’ expectations of $5.25 million. During the same period in the previous year, the business earned $0.02 earnings per share. As a group, analysts predict that Sono-Tek will post 0.07 EPS for the current fiscal year.
Sono-Tek Company Profile
Sono-Tek Corporation designs and manufactures ultrasonic coating systems for applying on parts and components for the microelectronics/electronics, alternative energy, medical, industrial, and research and development/other markets worldwide. The company also designs and manufactures custom-engineered ultrasonic coating systems; and provides nozzles and generators for manufacturers' equipment.
See Also
- Five stocks we like better than Sono-Tek
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Palantir’s New Healthcare Deal Boosts AI and Data Reach
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- GM’s Billion-Dollar Bruise: GM’s Strategic Pivot Makes It a Buy
- Which Wall Street Analysts are the Most Accurate?
- Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
Receive News & Ratings for Sono-Tek Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sono-Tek and related companies with MarketBeat.com's FREE daily email newsletter.
